...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Rumors starting again

I myself have not heard these rumours this time but like you and RVXOT would not trust them, even if they came directly off the company website. I will trust something they say once the money comes through.  For me tax implications would be a distant secondary concern if something really good happened at either company or both.

Don said directly on the RVX webcast "we will see activity before the end of the year" on the RVX side. We shall see, I will be pleasantly surprised if he has finally given shareholders some accurate guidance. Perhaps we will get something on the Zenith side that will provide some tangible benefit to shareholders. The science seems to be moving along quite well and there definitely is a great deal of need in the areas Zenith is pursuing. 

Share
New Message
Please login to post a reply